Clinical Trial

Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

Study acronym: TAXIO
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The current study is intended to be a "proof of concept" to evaluate the potential value of synergy between paclitaxel carboplatin and immunotherapy. If a signal clearly shows superiority over the CASPIAN data , we will have arguments to think that the combination of paclitaxel and carboplatin is more suitable for synergy with immunotherapy than the standard etoposide and carboplatin.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-02 -> 2026-11 2026-08-12
minor Completion pushed: 2028-02 -> 2028-11 2026-08-12
Trial Details
NCT Number NCT05856695
Lead Sponsor Intergroupe Francophone de Cancerologie Thoracique
Conditions Small Cell Lung Cancer Extensive Stage
Enrollment 67 participants
Start Date 2023-11-17
Primary Completion 2026-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-11